



Pharming Business Update

Rein Strijker

April 3, 2008

This presentation contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Pharming - Overview



KEY FACTS

- Public company on NYSE Euronext (*Ticker: PHARM*)
- Operational base in Netherlands and US with 90 employees
- Late stage products
- Product focus - Biopharmaceuticals, Biomaterials and Bionutritionals
- Technology platforms - Protein production, Tissue repair, DNA repair
- Management team with strong pharma and biotech trackrecord



Francis Pinto
Chief Executive Officer



Rein Strijker
Chief Commercial Officer



Bruno Giannetti
Chief Operations Officer

Product pipeline

Product	Indication	R&D/Pre-clinic	Phase I	Phase II	Phase III	Mkt
Rhucin®	HAE	Pharma				
rhC1INH	New Ind.	Pharma				
Prodarsan®	Prem. Ageing	Pharma				
rhFIB	Bleeding	Pharma				
DNage	Ageing dis.	Pharma				
rhCOL	Tissue rep.	Pharma				
hLF	Nutritional				Nutrition GRAS	
DNage	Nutritional	Nutrition GRAS				

Pharma

Nutrition